Investigation into alternative sugars as potential carriers for dry powder formulation of budesonide

BioImpacts

Volumn 1, Issue 2, 2011, Pages 105-111

  Momin, Mohammed Nurul ^a   Hedayati, Atoosa ^a   Nokhodchi, Ali ^a  

^a MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

Author keywords

Budesonide; Dry powder inhaler; Fine particle dose; Fine particle fraction; Physico Chemical properties

Indexed keywords

BUDESONIDE; GLUCOSE; MALTITOL; MANNITOL; SORBITOL; XYLITOL;

AEROSOL; ARTICLE; CARBOHYDRATE ANALYSIS; CONCENTRATION PROCESS; CONTROLLED STUDY; DRUG DETERMINATION; DRUG FORMULATION; DRUG MIXTURE; PARTICLE SIZE; POWDER INHALER; SCANNING ELECTRON MICROSCOPY; SPECTROMETRY;

EID: 84876698504     PISSN: 22285652     EISSN: 22285660     Source Type: Journal    
DOI: 10.5681/bi.2011.014     Document Type: Article

References (40)

1. Agertoft L, Pedersen S, Nikander K.1999. Drug delivery from the turbuhaler and Nebuhaler pressurised metered dose inhaler to various age groups of children with asthma. J Aerosol Med 12,161-169.
2. Borgstrom L, Derom E, Stahl E, Wahlin-Boll E, Pauwels R.1996. The inhalation device influences lung deposition and bronchodilating effect & terbutaline. Am J Respir Crit Care Med 153,1636-1640.
3. Byron PR, Patton JS.1994. Drug delivery via the respiratory tract. J Aerosol Med 71,49-75.
4. Brindley A, Sumby BS, Smith IJ, Prime D, Haywood PA, Grant AC.1995. Design, Manufacture and Dose Consistency of the Serevent Diskus Inhaler. Pharm Technol Eur 7,14-22.
5. British Thoracic Society, National Asthma Campaign, Royal College of Physicians. 1997. The British Guidelines on asthma management: 1995 review and position statement. Thorax 52, S1-29.
6. British Pharmacopoeia. 2000. Aerodynamic assessment of fine particles. HMSO. London Appendix X11F. A194-A200.
7. COPD Guidelines Group of Standards of Care Committee of the BTS. 1997. BTS guidelines for the management of chronic obstructive pulmonary disease. Thorax. 52, S1- 28.
8. Crompton GK, Virchow JC, Dal Negro RS, Pedersen A, Magnan J, Seidenberg, Barnes PJ.2007. Importance of inhaler devices in the management of airway disease, Elsevier Lt. Chew NYK, Chan HK. 1999. Influence of particle size, airflow and inhaler device on the dispersion of mannitol powders as aerosols. Pharm Res. 16,1098-1103.
9. Chew N.K., Bagster DF, Chan HK.2000. Effect of particle size, airflow, and inhaler device on the aerosolisation of disodium cromoglycate powders. Int J Pharm 206,75-83.
10. Daviskas E, Anderson SD,Eberl S, Chan HK., and Bautovich G.1999. Inhalation of dry powder mannitol improves of clearance of mucus in patients with bronchiectasis. Am J Crit 159,1843-1848.
11. Dolovich M.1995. Characterisation of medical aerosols: Physical and Clinical requirements for new inhalers. Aeroso Sci Tech 22,392-399.
12. European Pharmacopoeia. 1999. Preparations for inhalations: Aerodynamic assessment of fine particles, third ed. Council of Europe, Strasbourg, 143-150
13. Frijlink HW, de Boer AH.2004. Dry powder inhalers for pulmonary drug delivery, Expert Opinion on Drug Delivery 1,67-86.
14. Ganderton D, Kassem NM. 1992. Dry powder inhaler. Adv Pharm Sci, 165-191.
15. Gonda I. 1990. Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract. Crit Rev Ther Drug Carrier Syst. 6: 273
16. Kaialy W, Momin, M.N, Ticehurst, MD, Murphy I, Nokhodchi A. 2010. Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler. Colloids and Surfaces B, Biointerfaces, volume 79, issue 2, pages 345- 356.
17. Lipworth B, Clarke D. 1997. Lung delivery of salbutamol given by breath activated pressurised aerosol and dry powder inhaler of devices, Pulm Pharmacol Ther 10, 211-214.
18. Louey M, Van Oort M., Hickey A.2004. Aerosol dispersion of respirable particles in narrow size distributions produced by jet milling and spray drying techniques. Pharm Res 21,1200-1206.
19. Lucas P, Clarke M.J, Anderson K, Tobyn MJ, Staniforth JN. 1998. The role of fine particle excipients in pharmaceutical dry powder aerosols. Proceedings of Respiratory Drug Delivery. Interpharm Press.
20. Momin MN, Patel D, Nokhodchi A. July-September 2010. An Investigation on Alternative Sugars as Potential Carriers for Salbutamol Dry Powder Inhalers. Inventi Rapid, Pharm Tech 1(2).
21. Newman SP, Clarke SW.1983. Therapeutic aerosols. Physical and Practical considerations. Thorax, 38, 881-886.
22. O'Connor B. 2004. The ideal inhaler design characteristics improve outcomes, Respir Med 98, S10-S16.
23. Parry-Billings M., Design. 2000. Development and performance of a multidose dry powder inhaler. Pharm.Technol Eur 12, 38 -4
24. Patton JS, Platz RM.1992. Pulmonary delivery of peptides and proteins for systemic action. Adv Drug Deliv Rev 8,179-228.
25. Podczeck F. 1997. The relationship between particulate properties of carrier materials and the adhesion force of drug particles in interactive powder mixtures. J Adhesion Sci Technol 11,1089-1104.
26. Podczeck F. 1998. Adhesion forces in interactive powder mixtures of a micronized drug and carrier particles of various particle size distributions. J Adhes Sci Technol 12, 1323-1339
27. Steckel H. 2003. Inhalations pulver-Neuere Entwicklungen bei pulverinhalatoren Pz Prisma 3, 145- 157
28. Smyth HDC, Hickey AJ. 2005. Carriers in drug powder delivery: implications for inhalation system design. American Journal of Drug Delivery 3, 117-132
29. Snell NJC, Ganderton D. 1999. Assessing lung deposition of inhaled medications. Consensus statement form a workshop of the British Association for Lung Research held at the institute of Biology, London, UK on 17 April 1998. Respir Med 93, 123- 133.
30. Timsina MP, Martin GP, Marriott c, Ganderton D, Yianneskis M. 1994. Drug delivery to the respiratory tract using dry powder inhalers. Int J Pharm. 101, 1 -13.
31. Tee SK, Marriott C, Zeng XM, Martin GP. 2000. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate. Int J Pharm 208, 111- 123.
32. United States Pharmacopoeia. 1999. Physical tests and determinations: Aerosols, metered dose inhalers, and dry powder inhalers. The United States Pharmacopoeial Convention Inc. Rockville, MD., 4933-4949.
33. Visser J. 1989. Van der Waals and other cohesive forces affecting powder fluidization. Powder TechnoL. 58, 1- 10.
34. Zanen P, Vanspiegel PI, Vanderkolk H, Tushuizen E, Enthoven R.1992. The effect of the inhalation flow on the performance of a dry powder inhalation system. Int J Pharm 1,199-203.
35. Zanen P, Go LT, Lammers JWJ. 1994. The optimal particle size for b- adrenergic aerosols in mild asthmatics. Int J Pharm 107, 211- 217.
36. Zanen P, Go LT., Lammers JWJ. 1995. The optimal particle size for parasympathicolytic aerosols in mild asthmatics . Int J Pharm 114,111-115
37. Zeng XM, Martin GP., Marriott C. 2001. Particulate interactions in Dry Powder Formulations for inhalation. Taylor and Francis.
38. Zeng XM, Pandhal KH, Marin GP. 2000. The influence of lactose carrier on the content homogeneity and dispersibility of beclomethasone dipropionate from dry powder aerosols. Int J Pharm 197, 41.
39. Zeng XM. 1997. The influence of particle engineering on drug delivery by dry powder aerosols, Ph.D. thesis. University of London. London, UK..
40. Zimon AD. 1969. Adhesion of Dust and Powder, Plenum Press, New York.